Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT04965467

Fabry Aim Children Early (ACE) Project

Fabry Aim Children Early (ACE) Project-Screening for Fabry Disease in a Pediatric Population at Risk

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
Children's Hospital of Fudan University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the frequency of Fabry disease in children with early symptoms.

Detailed description

Fabry disease is a complex, multisystemic and clinically heterogeneous disease that commonly presents in childhood and is caused by deficient activity of the lysosomal enzyme alpha-galactosidaseA (α-gal A). Symptoms of Fabry disease in the pediatric population are well described. Symptoms can occur in early childhood, before age 5 years. Incidence estimations of Fabry disease vary widely. The true incidence is likely to be higher than originally thought, owing to the existence of milder variants of the disease. The purpose of this study is to assess the frequency of Fabry disease in children with early symptoms. Patients would benefit from early diagnosis, appropriate treatment, follow-up and surveillance. Early detection of Fabry patients would also benefit affected relatives, many of whom do not have a clear diagnosis of their clinical condition.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTScreening for Fabry diseaseA questionnaire specifically designed to assess Fabry disease-associated phenotypes in infancy, childhood and adolescence: pain in the hands and feet, angiokeratomas, hypohidrosis, corneal whorls, unexplained renal failure, unexplained hypertrophic myocardiopathy and unexplained early onset stroke. The questionnaire consisted mainly of quantitative, closed questions with pre- defined response options.The diagnosis of FD will be performed by standard procedures following international recommendations. These require the search for a deficiency of alphagalactosidase A activity on leucocytes in males and genetic analysis of the GLA gene in females (Germain et al. 2010). In females plasma Gb3, globotriaosyl- sphingosine (lyso-Gb3) will be measured for screening.

Timeline

Start date
2021-07-27
Primary completion
2022-02-20
Completion
2022-02-28
First posted
2021-07-16
Last updated
2021-09-30

Locations

21 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04965467. Inclusion in this directory is not an endorsement.